Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DOR Clear all
Terminated No phase listed Observational

LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm

NCT04695171
View directory record Official record
Conditions
Hiatal Hernia Large, Gastro Esophageal Reflux, Hiatal Hernia, Hiatal Hernia, Paraesophageal, Reflux, Gastroesophageal, Reflux Acid
Interventions
LINX Reflux Management System, Fundoplication
Device · Procedure
Lead sponsor
Foregut Research Foundation
Other
Eligibility
21 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Lone Tree, Colorado • Coral Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 4, 2026, 7:34 AM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 4, 2026, 7:34 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Doravirine and Weight Gain in Antiretroviral Naive

NCT05457530
View directory record Official record
Conditions
Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions
DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
Drug · Combination Product
Lead sponsor
Prism Health North Texas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 4, 2026, 7:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

NCT02225184
View directory record Official record
Conditions
Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence, Opiod-Related Disorders
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

NCT04470050
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 7:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian PRP for Diminished Ovarian Reserve

NCT05790655
View directory record Official record
Conditions
Diminished Ovarian Reserve
Interventions
oPRP, Placebo- Serum
Other
Lead sponsor
Generation Next Fertility
Other
Eligibility
35 Years to 42 Years · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252
View directory record Official record
Conditions
HIV-1 Infection
Interventions
MK-8591A
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720
View directory record Official record
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 7:34 AM EDT
Recruiting No phase listed Observational

Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy

NCT04948658
View directory record Official record
Conditions
Turner Syndrome, Post-menarcheal Adolescents, Ovarian Disfunction, Galactosemia, Variations in Sex Characteristics, Differences in Sex Development
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

NCT03332095
View directory record Official record
Conditions
HIV Infections
Interventions
Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

NCT04223778
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, ART
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 4, 2026, 7:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

NCT02179255
View directory record Official record
Conditions
Female Infertility Due to Diminished Ovarian Reserve
Interventions
Human Growth Hormone, Follicle Stimulating Hormone
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 4, 2026, 7:34 AM EDT
Recruiting Phase 2 Interventional

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 4, 2026, 7:34 AM EDT